<DOC>
	<DOCNO>NCT00706225</DOCNO>
	<brief_summary>Bazedoxifene ( BZA ) 20 mg tablet investigational medication ( approved FDA ) study possible prevention treatment postmenopausal osteoporosis . PREMARIN® ( conjugate estrogens [ CE ] ) approve FDA treat moderate severe symptom menopause ( i.e. , hot flash , and/or vulvar vaginal atrophy ) prevention postmenopausal osteoporosis . The purpose study evaluate pharmacokinetics ( absorption , distribution , breakdown elimination body ) single dose PREMARIN® administer together multiple dos bazedoxifene ( BZA ) healthy postmenopausal woman . Information also obtain regard safety tolerability study medication give together healthy postmenopausal woman .</brief_summary>
	<brief_title>Study Evaluating Potential Drug Interaction Of Bazedoxifene &amp; Premarin In Healthy Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Bazedoxifene</mesh_term>
	<criteria>Healthy , postmenopausal woman , ( either naturally surgically blood hormone level consistent postmenopausal state specify subject ) age 35 70 year , inclusive Have participate clinical drug study least 30 day prior study medication administration , Must history drug alcohol abuse within 1 year consume 2 standard unit per day alcohol ( standard unit equal 12 ounce beer , 1 ½ ounce 80proof alcohol 6 ounce wine ) Must either nonsmoker smoke less 10 cigarette per day , must able abstain smoking clinic confinement , Must donate plasma blood total study . All test result study criterion study meet . Only healthy postmenopausal woman eligible . Health assess clinical chemistry laboratory result physical exam .</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>